New hope for Tough-to-Treat myeloma: drug combo shows promise
NCT ID NCT05560399
First seen Jan 06, 2026 · Last updated Jun 13, 2026 · Updated 25 times
Summary
This early-phase study tests a new three-drug combination (iberdomide, elotuzumab, and dexamethasone) in adults with multiple myeloma that has returned or stopped responding to prior therapies. The goal is to find the safest dose and see if the combination can shrink tumors. About 37 participants will be enrolled to evaluate safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine
New York, New York, 10029, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.